Cargando…
Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb(3)) in Fabry Transgenic Mice and in the Plasma of Fabry Patients
Fabry disease (FD) results from mutations in the gene (GLA) that encodes the lysosomal enzyme α-galactosidase A (α-Gal A), and involves pathological accumulation of globotriaosylceramide (GL-3) and globotriaosylsphingosine (lyso-Gb(3)). Migalastat hydrochloride (GR181413A) is a pharmacological chape...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589404/ https://www.ncbi.nlm.nih.gov/pubmed/23472096 http://dx.doi.org/10.1371/journal.pone.0057631 |
_version_ | 1782261726475976704 |
---|---|
author | Young-Gqamana, Brandy Brignol, Nastry Chang, Hui-Hwa Khanna, Richie Soska, Rebecca Fuller, Maria Sitaraman, Sheela A. Germain, Dominique P. Giugliani, Roberto Hughes, Derralynn A. Mehta, Atul Nicholls, Kathy Boudes, Pol Lockhart, David J. Valenzano, Kenneth J. Benjamin, Elfrida R. |
author_facet | Young-Gqamana, Brandy Brignol, Nastry Chang, Hui-Hwa Khanna, Richie Soska, Rebecca Fuller, Maria Sitaraman, Sheela A. Germain, Dominique P. Giugliani, Roberto Hughes, Derralynn A. Mehta, Atul Nicholls, Kathy Boudes, Pol Lockhart, David J. Valenzano, Kenneth J. Benjamin, Elfrida R. |
author_sort | Young-Gqamana, Brandy |
collection | PubMed |
description | Fabry disease (FD) results from mutations in the gene (GLA) that encodes the lysosomal enzyme α-galactosidase A (α-Gal A), and involves pathological accumulation of globotriaosylceramide (GL-3) and globotriaosylsphingosine (lyso-Gb(3)). Migalastat hydrochloride (GR181413A) is a pharmacological chaperone that selectively binds, stabilizes, and increases cellular levels of α-Gal A. Oral administration of migalastat HCl reduces tissue GL-3 in Fabry transgenic mice, and in urine and kidneys of some FD patients. A liquid chromatography-tandem mass spectrometry method was developed to measure lyso-Gb(3) in mouse tissues and human plasma. Oral administration of migalastat HCl to transgenic mice reduced elevated lyso-Gb(3) levels up to 64%, 59%, and 81% in kidney, heart, and skin, respectively, generally equal to or greater than observed for GL-3. Furthermore, baseline plasma lyso-Gb(3) levels were markedly elevated in six male FD patients enrolled in Phase 2 studies. Oral administration of migalastat HCl (150 mg QOD) reduced urine GL-3 and plasma lyso-Gb(3) in three subjects (range: 15% to 46% within 48 weeks of treatment). In contrast, three showed no reductions in either substrate. These results suggest that measurement of tissue and/or plasma lyso-Gb(3) is feasible and may be warranted in future studies of migalastat HCl or other new potential therapies for FD. |
format | Online Article Text |
id | pubmed-3589404 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-35894042013-03-07 Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb(3)) in Fabry Transgenic Mice and in the Plasma of Fabry Patients Young-Gqamana, Brandy Brignol, Nastry Chang, Hui-Hwa Khanna, Richie Soska, Rebecca Fuller, Maria Sitaraman, Sheela A. Germain, Dominique P. Giugliani, Roberto Hughes, Derralynn A. Mehta, Atul Nicholls, Kathy Boudes, Pol Lockhart, David J. Valenzano, Kenneth J. Benjamin, Elfrida R. PLoS One Research Article Fabry disease (FD) results from mutations in the gene (GLA) that encodes the lysosomal enzyme α-galactosidase A (α-Gal A), and involves pathological accumulation of globotriaosylceramide (GL-3) and globotriaosylsphingosine (lyso-Gb(3)). Migalastat hydrochloride (GR181413A) is a pharmacological chaperone that selectively binds, stabilizes, and increases cellular levels of α-Gal A. Oral administration of migalastat HCl reduces tissue GL-3 in Fabry transgenic mice, and in urine and kidneys of some FD patients. A liquid chromatography-tandem mass spectrometry method was developed to measure lyso-Gb(3) in mouse tissues and human plasma. Oral administration of migalastat HCl to transgenic mice reduced elevated lyso-Gb(3) levels up to 64%, 59%, and 81% in kidney, heart, and skin, respectively, generally equal to or greater than observed for GL-3. Furthermore, baseline plasma lyso-Gb(3) levels were markedly elevated in six male FD patients enrolled in Phase 2 studies. Oral administration of migalastat HCl (150 mg QOD) reduced urine GL-3 and plasma lyso-Gb(3) in three subjects (range: 15% to 46% within 48 weeks of treatment). In contrast, three showed no reductions in either substrate. These results suggest that measurement of tissue and/or plasma lyso-Gb(3) is feasible and may be warranted in future studies of migalastat HCl or other new potential therapies for FD. Public Library of Science 2013-03-05 /pmc/articles/PMC3589404/ /pubmed/23472096 http://dx.doi.org/10.1371/journal.pone.0057631 Text en © 2013 Young-Gqamana et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Young-Gqamana, Brandy Brignol, Nastry Chang, Hui-Hwa Khanna, Richie Soska, Rebecca Fuller, Maria Sitaraman, Sheela A. Germain, Dominique P. Giugliani, Roberto Hughes, Derralynn A. Mehta, Atul Nicholls, Kathy Boudes, Pol Lockhart, David J. Valenzano, Kenneth J. Benjamin, Elfrida R. Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb(3)) in Fabry Transgenic Mice and in the Plasma of Fabry Patients |
title | Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb(3)) in Fabry Transgenic Mice and in the Plasma of Fabry Patients |
title_full | Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb(3)) in Fabry Transgenic Mice and in the Plasma of Fabry Patients |
title_fullStr | Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb(3)) in Fabry Transgenic Mice and in the Plasma of Fabry Patients |
title_full_unstemmed | Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb(3)) in Fabry Transgenic Mice and in the Plasma of Fabry Patients |
title_short | Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb(3)) in Fabry Transgenic Mice and in the Plasma of Fabry Patients |
title_sort | migalastat hcl reduces globotriaosylsphingosine (lyso-gb(3)) in fabry transgenic mice and in the plasma of fabry patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589404/ https://www.ncbi.nlm.nih.gov/pubmed/23472096 http://dx.doi.org/10.1371/journal.pone.0057631 |
work_keys_str_mv | AT younggqamanabrandy migalastathclreducesglobotriaosylsphingosinelysogb3infabrytransgenicmiceandintheplasmaoffabrypatients AT brignolnastry migalastathclreducesglobotriaosylsphingosinelysogb3infabrytransgenicmiceandintheplasmaoffabrypatients AT changhuihwa migalastathclreducesglobotriaosylsphingosinelysogb3infabrytransgenicmiceandintheplasmaoffabrypatients AT khannarichie migalastathclreducesglobotriaosylsphingosinelysogb3infabrytransgenicmiceandintheplasmaoffabrypatients AT soskarebecca migalastathclreducesglobotriaosylsphingosinelysogb3infabrytransgenicmiceandintheplasmaoffabrypatients AT fullermaria migalastathclreducesglobotriaosylsphingosinelysogb3infabrytransgenicmiceandintheplasmaoffabrypatients AT sitaramansheelaa migalastathclreducesglobotriaosylsphingosinelysogb3infabrytransgenicmiceandintheplasmaoffabrypatients AT germaindominiquep migalastathclreducesglobotriaosylsphingosinelysogb3infabrytransgenicmiceandintheplasmaoffabrypatients AT giuglianiroberto migalastathclreducesglobotriaosylsphingosinelysogb3infabrytransgenicmiceandintheplasmaoffabrypatients AT hughesderralynna migalastathclreducesglobotriaosylsphingosinelysogb3infabrytransgenicmiceandintheplasmaoffabrypatients AT mehtaatul migalastathclreducesglobotriaosylsphingosinelysogb3infabrytransgenicmiceandintheplasmaoffabrypatients AT nichollskathy migalastathclreducesglobotriaosylsphingosinelysogb3infabrytransgenicmiceandintheplasmaoffabrypatients AT boudespol migalastathclreducesglobotriaosylsphingosinelysogb3infabrytransgenicmiceandintheplasmaoffabrypatients AT lockhartdavidj migalastathclreducesglobotriaosylsphingosinelysogb3infabrytransgenicmiceandintheplasmaoffabrypatients AT valenzanokennethj migalastathclreducesglobotriaosylsphingosinelysogb3infabrytransgenicmiceandintheplasmaoffabrypatients AT benjaminelfridar migalastathclreducesglobotriaosylsphingosinelysogb3infabrytransgenicmiceandintheplasmaoffabrypatients |